FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average	burden					
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)														
Name and Address of Reporting Person * Clendeninn Neil James				2. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]						,	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer (give title below) Other (specify below)				
(Last) (First) (Middle) 1522 217TH PLACE SE, SUITE 100				3. Date of Earliest Transaction (Month/Day/Year) 05/31/2012											
(Street) BOTHELL, WA 98021			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqui						s Acquired	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		Date	2A. Deemed Execution Date, if) any (Month/Day/Year)		te, if	(Instr. 8)		Securities Acqual or Disposed of the next of the securities Acqual or Disposed of the next of the securities Acqual or Disposed of the next of the securities Acqual or Disposed or Dispos	f (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	L					ls, war	rants,	in this f display uired, Dispo , options, co	s who respond form are not rest a currently was sed of, or Bene envertible securi	equired to valid OME ficially Ow	respond control r	unless the	e form		474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		if Transaction of Code De Pri (Instr. 8) Se Ac (A Di of (Instr. 8) Se		of Deriva Securi Acquir (A) or Dispos of (D)	Expiration (Month/I writies quired or posed D) str. 3, 4,			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 12.56	05/31/2012		A		4,000)	(1)	05/31/2022	Commo	n 4,000	\$ 0	4,000	D	
Restricted Stock Units	(2)	05/31/2012		A		2,000		(3)	(4)	Commo	n 2,000	\$ 0	2,000	D	

Reporting Owners

D. C. O. N.	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Clendeninn Neil James 1522 217TH PLACE SE SUITE 100 BOTHELL, WA 98021	X						

Signatures

Sandra Thomson as attorney in-fact for Neil Clendeninn	06/04/2012
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest 100% on the earlier of May 31, 2013 or the date immediately prior to the issuer's next annual meeting of stockholders.
- (2) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- (3) The restricted stock units vest 100% on the earlier of the first anniversary of the grant date or the date immediately prior to the issuer's next annual meeting of stockholders.
- (4) The restricted stock units expire 30 days from the earlier of the first anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.